Goodwin’s Life Sciences team advised Rodin Therapeutics, Inc. as it completed a $27 million financing round. The financing will fuel the ongoing development of innovative product candidates designed to treat neurological disorders, such as Alzheimer’s disease and Parkinson’s disease.
Rodin Therapeutics is discovering and developing first in class therapeutics for neurological disorders, applying unique insights into the role of epigenetics and novel chemical strategies to target specific HDAC complexes. Rodin’s unique translational strategy, along with a targeted approach to synaptic resilience, has potential for multiple phenotypically diverse diseases – such as Parkinson’s disease, Alzheimer’s disease, frontotemporal dementia, post-traumatic stress disorder and traumatic brain injury – which all share the common root cause of impaired neuronal and synaptic function.
The Goodwin team was led by partner Chris Denn and included associates Bill Collins, Catherine Magazu and Michael Cohen.
For additional details on the financing, please read the press release.